missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ GeneBLAzer™ PR-UAS-bla HEK 293T Cells

GeneBLAzer™ PR-UAS-bla HEK 293T Cells

Brand:  Invitrogen™ K1693


Additional Details : Weight : 0.01000kg

Product Code. 10003443

  • 10680.00 € / Each
Estimated Shipment: 02-07-2024
to see stock.
Add to basket

Description

Description

PR-UAS-bla HEK 293T cells contain the ligand-binding domain (LBD) of the human Progesterone Receptor (PR) fused to the DNAbinding domain of GAL4 stably integrated in the GeneBLAzer™UAS-bla HEK 293T cell line. GeneBLAzer™UAS-bla HEK 293T cells stably express a beta-lactamase reporter gene under the transcriptional control of an upstream activator sequence (UAS). When an agonist binds to the LBD of the GAL4 (DBD)-PR (LBD) fusion protein, the protein binds to the UAS, resulting in expression of beta-lactamase. Division Arrested (DA) cells are available in two configurations- an Assay Kit (which includes cells and sufficient substrate to analyze 1 x 384- well plate), and a tube of cells sufficient to analyze 10 x 384-well plates. PR-UAS-bla HEK 293T cells are functionally validated for Z' and EC50 concentrations of R5020. In addition, PR-UAS-bla HEK 293T cells have been tested for assay performance under variable conditions, including DMSO concentration, cell number, stimulation time, and substrate loading time (data available upon request). Additional testing data using alternate stimuli are also available.
Specifications

Specifications

-80°C
Fluorescent
2 x 106 Cells
Cell Line
GeneBLAzer™ PR-UAS-bla HEK 293T Cells, 2 x 106 cells, Liquid, HEK 293T Cell Line, Human Species, Dividing Cells State, Fluorescent Detection Method, Nuclear Receptors Target, BLA (Beta-Lactamase) Reporter, Epithelial Cell Phenotype, Adherent Growth Properties
Pharma and biopharma, target and lead identification and validation
293T (HEK)
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Special Offers

Special Offers

For Research Use Only. Not for use in diagnostic procedures.